Loading…
Keros Therapeutics, Inc. is projected to rise to $12.26 by 2027, a +8% move from its current price of $11.31. KROS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $10.97 | $11.31 | $11.67 | +0.03% |
| May 30 | $10.83 | $11.32 | $11.83 | +0.06% |
| May 31 | $10.72 | $11.32 | $11.95 | +0.09% |
| Jun 1 | $10.64 | $11.32 | $12.05 | +0.12% |
| Jun 2 | $10.56 | $11.33 | $12.15 | +0.15% |
| Jun 3 | $10.50 | $11.33 | $12.23 | +0.18% |
| Jun 4 | $10.43 | $11.33 | $12.31 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.43 | $11.33 | $12.31 | +0.21% |
| Week 2 | $10.10 | $11.36 | $12.76 | +0.41% |
| Week 3 | $9.86 | $11.38 | $13.13 | +0.62% |
| Week 4 | $9.67 | $11.40 | $13.45 | +0.83% |
| Week 5 | $9.50 | $11.43 | $13.74 | +1.04% |
| Week 6 | $9.35 | $11.45 | $14.02 | +1.24% |
| Week 7 | $9.22 | $11.47 | $14.28 | +1.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
Keros Therapeutics was incorporated in 2015 and is headquartered in Lexington, Massachusetts. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd.
to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds.
Keros Therapeutics, Inc. (KROS) is currently trading at $11.19 per share. Its market capitalization is $221.47M, and it ranks 3782.
The year-by-year forecast presents a long-term bullish outlook, with average prices rising from $11.19 in 2026 to $55.74 in 2050 and corresponding ROIs reaching as high as 398.1% by 2050. The forecast highlights Neutral sentiment in 2026 and 2027, followed by Bullish sentiment from 2028 through 2050. This trajectory suggests meaningful upside potential over the long term, albeit with varying annual returns and notable uncertainty around near-term movements.
A major floor 21.0% below — a decisive break under it would weaken the trend.
The nearest floor, 12.4% below — buyers have tended to step in here.
The nearest ceiling, 6.7% above — a clean break opens room to run.
A major ceiling 72.1% above — clearing it would confirm fresh momentum.
Key KROS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KROS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.19 | Buy | $11.14 | Buy |
| MA 10 | $10.95 | Buy | $11.12 | Buy |
| MA 20 | $11.29 | Buy | $11.23 | Buy |
| MA 50 | $11.38 | Sell | $11.88 | Sell |
| MA 100 | $13.89 | Sell | $13.20 | Sell |
| MA 200 | $15.31 | Sell | $15.23 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.80 | Neutral |
| Stoch RSI (14) | 74.66 | Neutral |
| CCI (20) | 2.81 | Neutral |
| Williams %R (14) | -35.19 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -6.30 | Sell |
| Bollinger %B (20,2) | 0.51 | Neutral |
| Stochastic %K (14) | 64.81 | Neutral |
| TRIX (15) | -0.21 | Sell |
| Awesome (5,34) | -0.20 | Sell |
| Ultimate (7,14,28) | 59.51 | Neutral |
| Momentum (10) | -0.34 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 11.46 | Sell |
| ADX (14) | 12.76 | Neutral |
| ATR (14) | 0.29 | Info |
The 30-day technical picture is Bearish. RSI14 is 50, indicating a neutral short-term momentum.
The 50-day simple moving average is $11.37 and the 200-day simple moving average is $15.33, which can act as near-term references for price action. Support is at $9.91 and resistance at $12.07.
The 30-day price range spans from $8.99 to $13.92, and annualized volatility is 60, underscoring notable short-term fluctuation potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.91 | $11.31 | $15.72 | 0% | Neutral | |
| $9.58 | $12.26 | $16.68 | +8% | Neutral | |
| $11.17 | $14.75 | $20.89 | +30% | Bullish | |
| $12.57 | $17.04 | $24.91 | +51% | Bullish | |
| $12.64 | $17.53 | $26.32 | +55% | Bullish | |
| $12.34 | $17.49 | $26.87 | +55% | Bullish | |
| $11.67 | $16.89 | $26.49 | +49% | Bullish | |
| $12.34 | $18.19 | $29.08 | +61% | Bullish | |
| $12.76 | $19.17 | $31.17 | +69% | Bullish | |
| $13.87 | $21.19 | $35.03 | +87% | Bullish | |
| $15.07 | $24.95 | $44.10 | +121% | Bullish | |
| $29.73 | $56.64 | $110.39 | +401% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $9.91 | $11.31 | $13.36 | +0.00% |
| June 2026 | $9.96 | $11.74 | $14.18 | +3.78% |
| July 2026 | $9.77 | $11.62 | $14.25 | -1.02% |
| August 2026 | $9.73 | $11.66 | $14.48 | +0.37% |
| September 2026 | $10.19 | $12.29 | $15.41 | +5.41% |
| October 2026 | $10.35 | $12.55 | $15.87 | +2.14% |
| November 2026 | $10.02 | $12.21 | $15.56 | -2.71% |
| December 2026 | $10.00 | $12.26 | $15.72 | +0.35% |
Click any year to see its month-by-month KROS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, KROS is projected to trade between $9.91 and $15.72, averaging $11.31 — a potential gain of 0% from today's $11.31. Price action looks broadly range-bound.
Keros Therapeutics, Inc.'s 2027 outlook centres on $12.26, within a $9.58 to $16.68 range. That is up +8% on the projected 2026 average. That marks a +8% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, KROS could reach as high as $20.89, with a base case around $14.75 and support toward $11.17 — roughly +30% from $11.31. Momentum favours further upside here.
Expect KROS to range from $12.57 to $24.91 through 2029. The $17.04 average target implies a +51% move from current prices. That is up +16% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The KROS price prediction for 2030 points to an average of $17.53 (low $12.64, high $26.32) — a potential gain of +55% on today's $11.31. Momentum favours further upside here.
In 2031, KROS is projected to trade between $12.34 and $26.87, averaging $17.49 — a potential gain of +55% from today's $11.31. That is 0% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
Keros Therapeutics, Inc.'s 2032 outlook centres on $16.89, within a $11.67 to $26.49 range. That is -3% versus the projected 2031 average. That marks a +49% change versus current levels. Momentum favours further upside here.
By 2033, KROS could reach as high as $29.08, with a base case around $18.19 and support toward $12.34 — roughly +61% from $11.31. Buyers look set to stay in control over this stretch.
Expect KROS to range from $12.76 to $31.17 through 2034. The $19.17 average target implies a +69% move from current prices. That is up +5% on the projected 2033 average. Momentum favours further upside here.
The KROS price prediction for 2035 points to an average of $21.19 (low $13.87, high $35.03) — a potential gain of +87% on today's $11.31. Buyers look set to stay in control over this stretch.
In 2040, KROS is projected to trade between $15.07 and $44.10, averaging $24.95 — a potential gain of +121% from today's $11.31. That is up +18% on the projected 2035 average. Momentum favours further upside here.
Keros Therapeutics, Inc.'s 2050 outlook centres on $56.64, within a $29.73 to $110.39 range. That is up +127% on the projected 2040 average. That marks a +401% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in KROS today (≈ 88.41733 KROS) could be worth
$5,008.25
+$4,008.25 (+401%) by 2050 · US Dollar
Based on the average projected KROS price of $56.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KROSwould be worth at today's price.
$1,000 invested in KROS on May 27, 2025 (≈ 69.686409 KROS) would be worth
$788.15
-$211.85 (-21.2%) today · 0.79× · US Dollar
Based on a KROS entry price of $14.35 vs. today's $11.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.98 | $1,030.05 | +3.0% |
| 1 month ago | $11.01 | $1,027.25 | +2.7% |
| 3 months ago | $15.03 | $752.5 | -24.8% |
| 6 months ago | $17.48 | $647.03 | -35.3% |
| 1 year ago | $14.35 | $788.15 | -21.2% |
| All time (5.0y) ago | $51.48 | $219.7 | -78.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KROS forecast.
Our base-case forecast reaches $23.00 around 2040.
Implied market cap at $23.00: $455.21M
The multi-year forecast shows bullish sentiment beginning in 2028 and persisting through 2050. The 2026 average is $11.19 and remains neutral, with a 2027 average of $12.04 also neutral. From 2028 onward, averages rise to $14.53 (2028), $17.05 (2029), $17.31 (2030), $17.16 (2031), $16.71 (2032), $17.75 (2033), $18.60 (2034), $20.85 (2035), $24.13 (2040), and $55.74 (2050).
ROI progresses from 0% in 2026 to 7.6% in 2027, 29.9% in 2028, 52.4% in 2029, 54.6% in 2030, 53.3% in 2031, 49.3% in 2032, 58.6% in 2033, 66.2% in 2034, 86.3% in 2035, 115.7% in 2040, and 398.1% in 2050.
The forecast is bullish for the long horizon, with the 2050 max forecast at $111.38 and a 2050 average of $55.74, indicating substantial upside potential relative to the current price. These figures are estimates and not guarantees, and actual results will vary with clinical, regulatory, and market developments.
Tap a question to reveal the answer.
The 2030 forecasted average price is $17.31, with a 2030 min of $12.31 and a max of $26.35. The ROI for 2030 is 54.6%, and sentiment is Bullish.
Forecasts show Neutral sentiment in 2026 and 2027, turning Bullish from 2028 onward, with rising averages and positive ROIs through 2050 (e.g., 54.6% in 2030 and 398.1% in 2050). These are estimates, not guarantees.
Yes. The 2050 max forecast is $111.38, which would exceed $50, and the 2040 max is $43.58 and the 2035 max is $35.11, showing progression toward higher levels over time.
Current price is $11.19 per share and market capitalization is $221.47M. The stock ranks 3782.
Bearish sentiment is indicated. RSI14 is 50. SMA50 is $11.37, SMA200 is $15.33. Support is at $9.91 and resistance at $12.07. The 30-day range is $8.99 to $13.92, and annualized volatility is 60.
Keros Therapeutics, Inc. Community Discussion
0Share your Keros Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.